Key Event: Outcome of Board Meeting
The Board of Directors of Orchid Pharma Limited held a meeting on October 20, 2026. The meeting commenced at 11:00 A.M. IST and concluded at 11:50 A.M. IST.
Board Resolution
The Board considered and approved a proposal (termed an 'Enabling Resolution') to explore potential market opportunities for raising funds. The approved fundraising is for an indicative aggregate amount of up to ₹600 Crores (Rupees Six Hundred Crore Only).
Fundraising Instruments and Methods
The funds may be raised by way of issue of:
- Equity shares
- Any other eligible securities or instruments
- Fully or partly convertible debentures
The permissible modes of issuance include:
- Qualified institutions placement (QIP)
- Private placement
- Public issue of equity shares
- Public issue of debt securities
- Preferential issue
- Any other permissible mode
- Or any combination thereof
Approvals Required
The fundraising proposal is subject to:
- Statutory approvals as may be required
- Regulatory approvals as may be required
- Approval of the members of the Company (shareholders), wherever applicable
- Such other approvals, permissions, and consents as may be necessary
Annexure A Details (Regulation 30 Compliance)
The annexure provides information as required under the SEBI circular:
- Type of securities proposed: Details are not available as the resolution is enabling in nature; specific securities will be determined based on market opportunities.
- Type of Issuance: Details are not available as the resolution is enabling.
- Total number of securities/amount: Approximately ₹600 Crores.
- Cancellation or termination: Not Applicable.
Filing and Submission
The disclosure was submitted to the National Stock Exchange of India Limited and BSE Limited. The document was digitally signed by Kapil Dayya, Company Secretary & Compliance Officer (Membership No. F10698), on October 20, 2026, at 12:07:40 IST.
#Tags: #OrchidPharma #Fundraising #SEBIDisclosure #RegulatoryCompliance #CorporateFinance